Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advances
Introduction To identify the most effective treatment for juvenile dermatomyositis (JDM), considering efficacy, safety, impact on patients and improvement in their quality of life. Material and Methods A systematic review was carried out comparing known treatments and immunobiological therapies, ev...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2024-12-01
|
| Series: | Rheumatology |
| Subjects: | |
| Online Access: | https://reu.termedia.pl/Immunobiologics-in-juvenile-dermatomyositis-a-systematic-review-of-promising-therapeutic,195799,0,2.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584807312261120 |
|---|---|
| author | Aline Maria de Oliveira Rocha Gabriel Fidelis Ribeiro Juliana Capecce Silva |
| author_facet | Aline Maria de Oliveira Rocha Gabriel Fidelis Ribeiro Juliana Capecce Silva |
| author_sort | Aline Maria de Oliveira Rocha |
| collection | DOAJ |
| description | Introduction
To identify the most effective treatment for juvenile dermatomyositis (JDM), considering efficacy, safety, impact on patients and improvement in their quality of life.
Material and Methods
A systematic review was carried out comparing known treatments and immunobiological therapies, evaluating clinical improvement, adverse events and prognosis. The MEDLINE, PubMed, LILACS and Cochrane Library databases were used with children aged 0 to 18 diagnosed with JDM. The PRISMA 2020 statement was followed throughout the process.
Results
The immunobiologics studied were rituximab (RTX) and anti-tumor necrosis factor drugs and used the Disease Activity Score to skin, Childhood Myositis Assessment Scale and Manual Muscle Testing tools. There was no difference in the response when RTX was used (early or late). The anti-TNF studies were carried out in a population that was refractory to the initial treatment and showed a significant improvement in muscle and skin disease activity.
Conclusions
For severe or refractory disease, biologics tend to be the medication with the best therapeutic response. |
| format | Article |
| id | doaj-art-9c4c36117bda4f3eb3cf8414730e7b5d |
| institution | Kabale University |
| issn | 0034-6233 2084-9834 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Rheumatology |
| spelling | doaj-art-9c4c36117bda4f3eb3cf8414730e7b5d2025-01-27T11:21:26ZengTermedia Publishing HouseRheumatology0034-62332084-98342024-12-0162644745510.5114/reum/195799195799Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advancesAline Maria de Oliveira Rocha0https://orcid.org/0000-0002-4253-9931Gabriel Fidelis Ribeiro1https://orcid.org/0000-0002-7266-045XJuliana Capecce Silva2https://orcid.org/0009-0007-3909-607XDepartment of Pediatric, Federal University of São Paulo, BrazilUniversity Center São Camilo, BrazilUniversity Center São Camilo, BrazilIntroduction To identify the most effective treatment for juvenile dermatomyositis (JDM), considering efficacy, safety, impact on patients and improvement in their quality of life. Material and Methods A systematic review was carried out comparing known treatments and immunobiological therapies, evaluating clinical improvement, adverse events and prognosis. The MEDLINE, PubMed, LILACS and Cochrane Library databases were used with children aged 0 to 18 diagnosed with JDM. The PRISMA 2020 statement was followed throughout the process. Results The immunobiologics studied were rituximab (RTX) and anti-tumor necrosis factor drugs and used the Disease Activity Score to skin, Childhood Myositis Assessment Scale and Manual Muscle Testing tools. There was no difference in the response when RTX was used (early or late). The anti-TNF studies were carried out in a population that was refractory to the initial treatment and showed a significant improvement in muscle and skin disease activity. Conclusions For severe or refractory disease, biologics tend to be the medication with the best therapeutic response.https://reu.termedia.pl/Immunobiologics-in-juvenile-dermatomyositis-a-systematic-review-of-promising-therapeutic,195799,0,2.htmljuvenile dermatomyositispharmaceuticalimmunobiologicspediatric rheumatology |
| spellingShingle | Aline Maria de Oliveira Rocha Gabriel Fidelis Ribeiro Juliana Capecce Silva Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advances Rheumatology juvenile dermatomyositis pharmaceutical immunobiologics pediatric rheumatology |
| title | Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advances |
| title_full | Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advances |
| title_fullStr | Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advances |
| title_full_unstemmed | Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advances |
| title_short | Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advances |
| title_sort | immunobiologics in juvenile dermatomyositis a systematic review of promising therapeutic advances |
| topic | juvenile dermatomyositis pharmaceutical immunobiologics pediatric rheumatology |
| url | https://reu.termedia.pl/Immunobiologics-in-juvenile-dermatomyositis-a-systematic-review-of-promising-therapeutic,195799,0,2.html |
| work_keys_str_mv | AT alinemariadeoliveirarocha immunobiologicsinjuveniledermatomyositisasystematicreviewofpromisingtherapeuticadvances AT gabrielfidelisribeiro immunobiologicsinjuveniledermatomyositisasystematicreviewofpromisingtherapeuticadvances AT julianacapeccesilva immunobiologicsinjuveniledermatomyositisasystematicreviewofpromisingtherapeuticadvances |